Coral Labs.

Why is Coral Laboratories Ltd falling/rising?

As of 31-Jul, Coral Laboratories Ltd's stock price is at 574.35, reflecting a decline of 0.97%. Despite a strong year-to-date performance, recent trends show underperformance against the Sensex and potential short-term weakness, although increased investor participation indicates some interest.

As of 31-Jul, Coral Laboratories Ltd's stock price is falling, currently at 574.35, which reflects a decrease of 5.65 or 0.97%. This decline is evident in the stock's performance over various periods; it has underperformed compared to the benchmark Sensex, with a 1-week drop of 1.31% while the Sensex gained 2.68%. Over the past month, the stock has decreased by 5.60%, contrasting with the Sensex's increase of 1.52%. <BR><BR>Despite a strong year-to-date performance of +30.98%, the recent trends indicate a downturn, particularly as the stock has underperformed its sector by 0.79% today. Although the stock is trading above its 5-day, 50-day, 100-day, and 200-day moving averages, it is below the 20-day moving average, suggesting a potential short-term weakness. <BR><BR>On a positive note, there has been a significant increase in investor participation, with delivery volume rising by 108.55% against the 5-day average, indicating some interest from investors. However, the overall liquidity remains adequate for trading, but the recent performance metrics suggest that the stock is currently facing downward pressure.

Which are the latest news on Coral Labs.?

Should I buy, sell or hold Coral Laboratories Ltd?

How big is Coral Labs.?

As of 10th June, Coral Laboratories Ltd has a market capitalization of 179.00 Cr, with recent net sales of 85.89 Cr and a net profit of 16.38 Cr. Shareholder's funds are 201.21 Cr, and total assets are valued at 229.46 Cr.

As of 10th June, Coral Laboratories Ltd has a market capitalization of 179.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Coral Laboratories reported Net Sales of 85.89 Cr and a Net Profit of 16.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 201.21 Cr and Total Assets valued at 229.46 Cr.

Who are in the management team of Coral Labs.?

The management team of Coral Labs includes Sheela R Kamdar (Independent Director), Girish Dhameja (Whole-time Director), Sushma Shashi Kadkade (Director & CFO), Saurabh Shah (Independent Director), Ruchi Anjaria (Company Secretary & Compliance Officer), Malay Doshi (Independent Director), and Rajendrasinh Rana (Director).

The management team of Coral Labs includes the following individuals:<BR><BR>1. **Sheela R Kamdar** - Independent Director<BR>2. **Girish Dhameja** - Whole-time Director<BR>3. **Sushma Shashi Kadkade** - Director & CFO<BR>4. **Saurabh Shah** - Independent Director<BR>5. **Ruchi Anjaria** - Company Secretary & Compliance Officer<BR>6. **Malay Doshi** - Independent Director<BR>7. **Rajendrasinh Rana** - Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Coral Labs.?

Coral Labs.' peers include Brooks Lab., Oxygenta Pharma, Sanjiv.Parant., Natural Capsules, Panch.Organics, and Quest Laborato. Coral Labs. has a Below Average management risk and growth, with a 1-year return of -15.19%, better than Oxygenta Pharma's -60.96% but lower than Guj. Inject(Ker)'s 427.17%.

Peers: The peers of Coral Labs. are Brooks Lab., Oxygenta Pharma, Sanjiv.Parant., Natural Capsules, Panch.Organics, and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Quest Laborato., while Average management risk is found at Panch.Organics. Below Average management risk is noted at Brooks Lab., Oxygenta Pharma, Coral Labs., Natural Capsules, and the rest. Good growth is seen at Sanjiv.Parant. and Quest Laborato., while Below Average growth is present at Brooks Lab., Oxygenta Pharma, Coral Labs., Natural Capsules, and the rest. Excellent capital structure is noted at Coral Labs., Panch.Organics, and Quest Laborato., while Below Average capital structure is found at Brooks Lab., Oxygenta Pharma, Natural Capsules, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Inject(Ker) at 427.17%, while the peer with the lowest 1-year return is Oxygenta Pharma at -60.96%. Coral Labs.'s 1-year return is -15.19%, which is higher than Oxygenta Pharma's but lower than Guj. Inject(Ker). Additionally, several peers, including Brooks Lab., Oxygenta Pharma, Sanjiv.Parant., Natural Capsules, and Panch.Organics, have negative six-month returns.

What does Coral Labs. do?

Coral Laboratories Ltd is a micro-cap pharmaceutical company established in 1997, specializing in manufacturing various pharmaceutical formulations. As of March 2026, it reported net sales of ₹26 Cr and a net profit of ₹5 Cr, with a market cap of ₹179 Cr.

Overview:<BR>Coral Laboratories Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focused on manufacturing pharmaceutical formulations such as tablets, capsules, liquid, and topical preparations.<BR><BR>History:<BR>Coral Laboratories Ltd was established in February 1997 and was promoted by Navin B Doshi of the DWD Group. The company came public in March 1994, raising funds of Rs. 2.5 Crore. It set up an additional ultra-modern manufacturing unit in Daman, which commenced commercial production in March 2004. The latest reported quarterly results show net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 26 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 5 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 179 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.30%<BR>- Debt Equity: -0.47<BR>- Return on Equity: 7.72%<BR>- Price to Book: 0.86<BR><BR>Contact Details:<BR>- Address: SF-206 Silver Oak Complex, BPC Road Vadodara Gujarat : 390020<BR>- Tel: 91-022-2500 5245/46<BR>- Email: cs@corallab.com<BR>- Website: http://www.corallab.com

Are Coral Laboratories Ltd latest results good or bad?

Coral Laboratories Ltd's latest results show strong profitability with a 87.77% increase in net profit for Q4 FY26, but revenue declined 5.87% year-on-year, raising concerns about demand sustainability and long-term growth. Investors should consider these mixed signals carefully.

Coral Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a significant increase in net profit for Q4 FY26, reporting ₹5.22 crore, which is an impressive 87.77% increase quarter-on-quarter. This indicates strong profitability improvements and effective cost management, as reflected in the operating margin, which expanded to 23.41%, up from 9.53% in the same quarter last year.<BR><BR>However, there are concerns regarding revenue, which saw a decline of 5.87% year-on-year, falling from ₹28.13 crore in Q4 FY25 to ₹26.48 crore in Q4 FY26. While there was a sequential improvement of 22.82% compared to the previous quarter, the year-on-year drop raises questions about the sustainability of demand and the company's competitive position in the market.<BR><BR>Overall, while the profitability metrics are encouraging and suggest operational efficiency, the decline in revenue and the company's long-term growth trajectory, which has seen negative trends over the past five years, are significant red flags. Investors should weigh these contrasting signals carefully.

When is the next results date for Coral Laboratories Ltd?

The next results date for Coral Laboratories Ltd is 30 May 2026.

The next results date for Coral Laboratories Ltd is scheduled for 30 May 2026.

Is Coral Labs. overvalued or undervalued?

As of November 17, 2025, Coral Labs is considered undervalued with a PE ratio of 10.25 and an EV to EBIT of 5.62, significantly lower than its expensive industry peers, suggesting potential for recovery despite a challenging year with a -40.17% stock return.

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.<BR><BR>In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex.

How has been the historical performance of Coral Labs.?

Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr during the same period.

Answer:<BR>The historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>Coral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from 174.35 Cr in March 2023 to 229.46 Cr in March 2025, with total liabilities increasing from 174.35 Cr to 229.46 Cr, indicating a proportional growth in the company's financial structure. Cash flow from operating activities, however, showed a negative trend, moving from a positive 12.00 Cr in March 2023 to a negative 1.00 Cr in March 2025, suggesting challenges in cash generation despite strong profit growth. Overall, Coral Labs has improved its financial performance significantly over the years, particularly in sales and profitability metrics.

Who are the top shareholders of the Coral Labs.?

The top shareholder of Coral Labs is Chetan Navinchandra Doshi, holding 51.54%. The highest public shareholder is Meeta Samir Sheth at 1.84%, with individual investors collectively owning 20.91% of the shares.

The top shareholders of Coral Labs are primarily the promoters, with Chetan Navinchandra Doshi holding the largest share at 51.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares. The highest public shareholder is Meeta Samir Sheth, who holds 1.84%. Additionally, individual investors collectively hold 20.91% of the shares.

What is the technical trend for Coral Labs.?

As of June 2, 2025, Coral Labs is in a bearish trend, supported by negative indicators across multiple time frames, including bearish MACD, RSI, Bollinger Bands, and moving averages.

As of 2 June 2025, the technical trend for Coral Labs has changed from mildly bearish to bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum shift. The RSI on a monthly basis is bearish, further supporting the bearish stance. Both the weekly and monthly Bollinger Bands are bearish, suggesting price volatility is trending downwards. Daily moving averages are also bearish, reinforcing the negative outlook. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on both time frames. Overall, the current technical stance is bearish with a strong emphasis on negative indicators across multiple time frames.

Has Coral Labs. declared dividend?

Coral Laboratories Ltd has declared a 20% dividend, amounting to 2 per share, with an ex-date of September 20, 2024. The company has shown varying total returns, with significant gains over the long term despite recent price fluctuations.

Coral Laboratories Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.33%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -24.78%, with a dividend return of 0%, resulting in a total return of -24.78%.<BR><BR>Over the past year, the price return was 18.66%, the dividend return was 0.35%, leading to a total return of 19.01%.<BR><BR>In the 2-year period, the price return was 157.18%, the dividend return was 0.84%, culminating in a total return of 158.02%.<BR><BR>For the 3-year period, the price return was 137.76%, the dividend return was 0.83%, resulting in a total return of 138.59%.<BR><BR>In the last 4 years, the price return was 31.4%, with a dividend return of 0.37%, leading to a total return of 31.77%.<BR><BR>Over the 5-year period, the price return was 214.6%, the dividend return was 1.00%, resulting in a total return of 215.6%.<BR><BR>Overall, Coral Laboratories Ltd has recently declared a dividend while showing varying total returns over different periods, with significant gains over the longer term despite some recent fluctuations in price returns.